Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 11;351(6278):1166-71.
doi: 10.1126/science.aad3517.

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni  1 , Sumeet A Khetarpal  1 , Daniel B Larach  1 , William F Hancock-Cerutti  2 , John S Millar  1 , Marina Cuchel  1 , Stephanie DerOhannessian  1 , Anatol Kontush  3 , Praveen Surendran  4 , Danish Saleheen  5 , Stella Trompet  6 , J Wouter Jukema  7 , Anton De Craen  8 , Panos Deloukas  9 , Naveed Sattar  10 , Ian Ford  11 , Chris Packard  12 , Abdullah al Shafi Majumder  13 , Dewan S Alam  14 , Emanuele Di Angelantonio  4 , Goncalo Abecasis  15 , Rajiv Chowdhury  4 , Jeanette Erdmann  16 , Børge G Nordestgaard  17 , Sune F Nielsen  17 , Anne Tybjærg-Hansen  18 , Ruth Frikke Schmidt  19 , Kari Kuulasmaa  20 , Dajiang J Liu  21 , Markus Perola  22 , Stefan Blankenberg  23 , Veikko Salomaa  20 , Satu Männistö  20 , Philippe Amouyel  24 , Dominique Arveiler  25 , Jean Ferrieres  26 , Martina Müller-Nurasyid  27 , Marco Ferrario  28 , Frank Kee  29 , Cristen J Willer  30 , Nilesh Samani  31 , Heribert Schunkert  32 , Adam S Butterworth  4 , Joanna M M Howson  4 , Gina M Peloso  33 , Nathan O Stitziel  34 , John Danesh  35 , Sekar Kathiresan  33 , Daniel J Rader  36 ; CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium
Collaborators, Affiliations

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni et al. Science. .

Abstract

Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted Scarb1 (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI. The P376L variant impairs posttranslational processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocyte-like cells derived from induced pluripotent stem cells from the homozygous subject, and in mice. Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have a profound HDL-related phenotype and an increased risk of CHD (odds ratio = 1.79, which is statistically significant).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. HDL composition and functionality in a SCARB1 P376L homozygote, heterozygous carriers, and controls
(A) FPLC fractionation of plasma lipoproteins from the P376L homozygote subject (red) and from a control with normal HDL-C. (B) Cholesterol, apoA-I, and apoA-II content in total HDL. (C) Free cholesterol (FC) and esterified cholesterol (CE) in total HDL (left) and the FC/CE ratio in total HDL (right). (D) HDL subclass concentrations after separation by density-gradient ultracentrifugation. (E) ApoA-I content in the same HDL subclasses. (F) ApoC-III content in the same HDL subclasses. (G) Cholesterol efflux capacity from macrophages of the THP-1 cell line. All data are reported as means ± SD.
Fig. 2
Fig. 2. SCARB1 P376L is a null variant in vitro and in vivo
(A) [3H] Cholesterol ether (CEt) uptake (left) and selective cholesterol uptake from HDL (right) in iPSC-derived HLCs from the P376L homozygote versus a noncarrier control. Cells were incubated with [3H]CEt and 125I-labeled tyramine cellobiose (TC) dual-labeled human HDL. All values are normalized to relative ALB gene expression in each cell line. All data represent mean values for wells of respective cell lines ± SD. (B) Plasma HDL cholesterol levels before and 12 days after AAV administration to Scarb1 KO mice. (C) [3H]Cholesterol ether (CEt) clearance (left) and fractional catabolic rate (right) from plasma of Scarb1 KO mice injected with null or SR-BI AAVs after administration of [3H]CE/125I-labeled TC dual-labeled human HDL. (D) 125I-labeled TC clearance (left) and fractional catabolic rate (right) from plasma after administration of dual-labeled HDL. (E) Selective cholesterol uptake in mice expressing null, SR-BI WT, or P376L measured by relative differences in 3H- and 125I-labeled fractional catabolic rates. (F) Sensitivity to Endo-H in P376L homozygous versus noncarrier iPSC-derived HLCs. Cell lysates of each genotype were treated with Endo-H to remove complex N-linked glycans from mature forms of proteins and then immunoblotted for SR-BI. Molecular weights of different forms of SR-BI after Endo-H treatment are given on the left. (G) SR-BI Endo-H sensitivity from liver lysates from mice expressing null, SR-BI WT, or SR-BI P376L AAV. Lysates were treated with Endo-H, followed by immunoblotting for SR-BI. Molecular weights of different forms of SR-BI after Endo-H treatment are given on the left. (A) Mean values for wells of respective cell lines ± SD; [(B) to (E)] means ± SD for each of the three groups. *P < 0.05; ** P < 0.01; ***P <0.001 by analysis of variance (ANOVA) [(B) and (C)]; plasma clearance, unpaired t test (E).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rader DJ, Tall AR. Nat Med. 2012;18:1344–1346. - PubMed
    1. Haase CL, et al. J Clin Endocrinol Metab. 2012;97:E248–E256. - PubMed
    1. Frikke-Schmidt R, et al. JAMA. 2008;299:2524–2532. - PubMed
    1. Voight BF, et al. Lancet. 2012;380:572–580. - PMC - PubMed
    1. Acton S, et al. Science. 1996;271:518–520. - PubMed

Publication types

MeSH terms

Associated data